Gilead Faces Sovaldi Patent Challenge: As seen in the Wall Street Journal.
Datamonitor Healthcare analyst suggests a slightly different approach
Medical-aid charity, Medecins du Monde (MDM), are challenging the European patent for blockbuster hepatitis C treatment, Sovaldi. The charity claims that the drug maker is “abusing” its patent and charging an “exorbitant” price that hinders access for many patients.
This is not the first time that Sovaldi’s patent has been challenged by a non-profit due to it’s high price tag. In India, a non-profit and generic drug maker recently teamed up to challenge the patent, arguing that the drug was not a significant improvement compared with an earlier compound developed by another company. This same argument is being used by MDM and is being advised by the same non-profit that filed the challenge in India.
Datamonitor Healthcare analyst, Michael Haydock, suggests that the patent challenge may not have the desired effect however. He says that MDM should target patents covering Harvoni, as opposed to Sovaldi, since this newer drug is likely to eventually replace Sovaldi as a widely used treatment.
“Harvoni is likely to have successed Sovaldi as the standard for care for the majority of patients by the time any patent litigation comes to an end,” he told the Wall Street Journal, “So generic versions would be unlikely to influence the treatment paradigm… Irrespective of patent litigation, EU prices are likely to drop considerably in the coming years as competition intensifies.”
To read the full article by Ed Silverman in the Wall Street Journal click here…
Posted in Infectious Diseases.